Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
American WellAMWL +0.17%50 3-Year EBITDA Growth Rate is 37.50% as of Jun. 2026, which is 2579% above its 10-year median of 1.40. GuruFocus rates AMWL with a GF Score™ of 50/100 and a GF Value™ of $6.41 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 526 Healthcare Providers & Services companies, American Well ranks better than 83.08% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 37.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 28.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of American Well was 37.50% per year. The lowest was -29.90% per year. And the median was 1.40% per year.
American Well (NYSE:AMWL) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
American Well 3-Year EBITDA Growth Rate Related Terms
AMWL vs LFMD, SY, HCAT: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, American Well's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
American Well 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, American Well's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where American Well's 3-Year EBITDA Growth Rate falls into.
American Well 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 37.50% mean?
American Well (AMWL) has a 3-Year EBITDA Growth Rate of 37.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for American Well and its competitors. This is 2579% above median its historical median of 1.40. According to the industry distribution chart, American Well ranks #89 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 16.9%.
Is American Well's 3-Year EBITDA Growth Rate too high?
American Well's current 3-Year EBITDA Growth Rate of 37.50% is 2579% above median its 10-year median of 1.40. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.05. American Well's value of 37.50% is 273.1% above this industry median. Based on the distribution chart, American Well ranks #89 out of 526 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, American Well has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does American Well's 3-Year EBITDA Growth Rate compare to LFMD and SY?
According to the Healthcare Providers & Services industry distribution chart, American Well ranks #89 out of 526 companies for 3-Year EBITDA Growth Rate. This places American Well in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.05. American Well's value of 37.50% is 273.1% above this benchmark. While the company's 10-year median is 1.40 vs. the industry median of 10.05, American Well has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. American Well's current 3-Year EBITDA Growth Rate of 37.50% is 273.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for American Well and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. American Well's current 3-Year EBITDA Growth Rate is 37.50%, which is 2579% above median its own 10-year median of 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is American Well stock overvalued right now?
Based on GuruFocus' analysis, American Well (AMWL) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.41, compared to a current price of $11.92 — trading 86% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 37.50%, which is 2579% above median its 10-year median of 1.40 and 273.1% above the Healthcare Providers & Services industry median of 10.05. American Well's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For American Well (AMWL), the current 3-Year EBITDA Growth Rate is 37.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is American Well (AMWL) Overvalued in 2026?
Based on GuruFocus' analysis, American Well stock appears to be overvalued.
The current stock price of $11.92 is trading 86% above its estimated GF Value™ of $6.41.
GuruFocus considers American Well to be Significantly Overvalued.
Key valuation signals for AMWL:
3-Year EBITDA Growth Rate: 37.50% (2579% above median its 10-year median of 1.40)
GF Value™: $6.41 vs. price of $11.92 (86% above fair value)
Industry Position: 273.1% above the Healthcare Providers & Services median (#89 of 526)
No single metric tells the full story. See the AMWL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.
50GF Score
Get the complete analysis for AMWL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMWL has been successfully added to your 
